Seelos Therapeutics (NASDAQ: SEEL) stock should rise 3,000% today. Given the recent stock price performance this should be welcome to SEEL stockholders. Except, of course, 3,000% or, 30x, is more unlikely to be a real stock price move. What’s much more likely is that we’ve a purely technical move here. One that’s entirely nominal which is indeed what is happening. There’s one specific problem that Seelos must solve and they’re going to do so. But no wallets will get fattened by their doing so.
We’ve looked before at Seelos Therapeutics: “Seelos Therapeutics (NASDAQ: SEEL) stock dropped 69% yesterday and a further 9% today. That’s 80% off SEEL stock in the one, slightly protracted, move. The reason why is the failure of the Phase II test. What might be worse is the reason for the failure. The observed results weren’t that bad if we’re to be honest about it. But there weren’t enough participants to achieve statistical relevance. And that’s bad, because that’s something that is under the control of the management.
The announcement: “Seelos Therapeutics, Inc. (SEEL) reported top line data showing clinically meaningful treatment effects across multiple endpoints and a well-tolerated safety profile from the double-blind, placebo-controlled cohort of its Phase II study of SLS-002 for Acute Suicidal Ideation and Behavior in adults with Major Depressive Disorder. The company said target enrollment of the study was 220 patients, however, due to financial constraints, only 147 patients were randomized. Due to the limited sample size, the study did not meet the pre-defined primary endpoint.”” That’s a badly designed test which is not a good sign.
Seelos Therapeutics stock price from Google Finance
That collapse of the stock price after the announcement of that test failure then produces a problem. Penny stocks, soon enough, lose their Nasdaq listing. So, something must be done. That something is to declare that 30 old shares are now one new one - a one for 30 reverse stock split: “Seelos Therapeutics, Inc. (SEEL) will effect a one-for-thirty (1-30) reverse split of its Common Stock. The reverse stock split will become effective on Tuesday, November 28, 2023.
This doesn’t change the market capitalisation, just the number of shares that make it up. Therefore the stock price reacts mechanically, rising 3,000% or 30x. That then drives the price over the Nasdaq $1 minimum bid price and the listing is saved. Well, until the next time, which does happen sometimes with pharma development stocks. This also doesn;t solve the basic business problem - designing a drug that works and therefore can be sold.